Ignite Creation Date:
2025-12-24 @ 7:24 PM
Ignite Modification Date:
2026-02-24 @ 10:22 PM
Study NCT ID:
NCT05005403
Status:
RECRUITING
Last Update Posted:
2025-10-28
First Post:
2021-08-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
Sponsor:
AbbVie
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Non-Small Cell Lung Cancer | View |
| None | Head and Neck Squamous Cell Carcinoma | View |
| None | Micro Satellite Stable Colorectal Cancer | View |
| None | Gastric/Esophageal Cancer | View |
| None | High-Grade Serous Ovarian Cancer | View |
| None | Pancreatic Cancer | View |
| None | Triple Negative Breast Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Non-Small Cell Lung Cancer | View |
| None | NSCLC | View |
| None | Head and Neck Squamous Cell Carcinoma | View |
| None | HNSCC | View |
| None | Solid Tumors | View |
| None | Budigalimab | View |
| None | ABBV-181 | View |
| None | ABBV-514 | View |
| None | Micro Satellite Stable Colorectal Cancer | View |
| None | MSS-CRC, Gastric Cancer | View |
| None | Esophageal Cancer | View |
| None | GEA | View |
| None | GEJ | View |
| None | High-Grade Serous Ovarian Cancer | View |
| None | HGSOC | View |
| None | Pancreatic Cancer, PDAC | View |
| None | Triple Negative Breast Cancer | View |
| None | TNBC | View |